The earnings call highlighted significant clinical progress, particularly with CX-2051, and strong financial positioning, although there were challenges with decreased revenue and common adverse events in clinical trials.

Company Guidance

During the CytomX Therapeutics Second Quarter 2025 Financial Results call, the company provided detailed guidance on its ongoing and future projects. The focus was on the clinical progress of CX-2051, a PROBODY antibody drug conjugate targeting EpCAM in colorectal cancer, which showed promising Phase I results with a 28% confirmed overall response rate, 94% disease control, and a preliminary progression-free survival of 5.8 months in a fifth-line CRC patient population. For CX-801, a masked interferon alpha-2b program, the company initiated a combination study with KEYTRUDA in metastatic melanoma, with initial data expected in 2026. Financially, CytomX completed a $100 million follow-on offering, ending the quarter with $158.1 million in cash and equivalents, providing a cash runway into Q2 2027. Revenue was $18.7 million, a decrease from the previous year, and operating expenses were reduced to $19.9 million. The company is focusing on advancing these potential treatments while maintaining disciplined capital allocation.

Promising Clinical Data for CX-2051

CX-2051 demonstrated a 28% confirmed overall response rate, 94% disease control, and 5.8 months of preliminary progression-free survival in the first 18 efficacy evaluable patients with CRC.

Strong Financial Position

CytomX completed a $100 million follow-on offering, bringing the total cash, cash equivalents, and investments to $158.1 million, with a projected cash runway to Q2 2027.

Progress in Clinical Programs

Enrollment for CX-2051 dose expansions is on track, and the first patient was dosed in the CX-801 and KEYTRUDA combination study in metastatic melanoma.

CytomX Therapeutics (CTMX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CTMX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.05 / -	0.07	―	―	―
Aug 07, 2025	2025 (Q2)	-0.06 / 0.00	-0.08	―	―
May 12, 2025	2025 (Q1)	0.13 / 0.27	0.17	58.82% (+0.10)
Mar 06, 2025	2024 (Q4)	-0.20 / 0.22	0.02	1000.00% (+0.20)	―
Nov 07, 2024	2024 (Q3)	-0.17 / 0.07	0.04	75.00% (+0.03)	―
Aug 08, 2024	2024 (Q2)	-0.10 / -0.08	-0.02	-300.00% (-0.06)	―
May 08, 2024	2024 (Q1)	-0.10 / 0.17	-0.05	440.00% (+0.22)	―
Mar 11, 2024	2023 (Q4)	-0.05 / 0.02	-0.42	104.76% (+0.44)	―
Nov 07, 2023	2023 (Q3)	-0.19 / 0.04	-0.35	111.43% (+0.39)	―
Aug 08, 2023	2023 (Q2)	-0.19 / -0.02	-0.37	94.59% (+0.35)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CTMX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.10	$2.35	+11.90%
May 12, 2025	$0.93	$2.13	+129.03%
Mar 06, 2025	$0.62	$0.66	+6.45%
Nov 07, 2024	$1.00	$1.09	+9.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CytomX Therapeutics Inc. (CTMX) report earnings?

CytomX Therapeutics Inc. (CTMX) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is CytomX Therapeutics Inc. (CTMX) earnings time?

CytomX Therapeutics Inc. (CTMX) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CTMX EPS forecast?

CTMX EPS forecast for the fiscal quarter 2025 (Q3) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing